In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Best of the Blog, IN VIVO, November 2009

Executive Summary

A selection of our favorite blog posts from November 2009 about stories not covered elsewhere in this issue of IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).

You may also be interested in...



FDA Updates Plavix Label, Leaves Effient With Clear Advantage

FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.

Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss

Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel